IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA

IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA

2023.11.30
Ceftolozane-tazobactam is a new BL-BLI combination drug, and ceftolozane is a third-generation cephalosporin antibiotic, and tazobactam is a beta-lactamase inhibitor. At the recent 2023 IDWeek in the United States, Dr. Ryan K. Shields from the University of Pittsburgh presented a real-world observational study assessing the effectiveness of ceftolozane-tazobactam compared to ceftazidime-avibactam in treating multidrug-resistant Pseudomonas aeruginosa (MDR-PA). He shared his insights in an interview with " Infectious Disease Frontline".
Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

2023.11.30
Staphylococcus aureus bacteremia is a major cause of bloodstream infections, and hospital-acquired bacterial pneumonia is often caused by multidrug-resistant bacteria. And developing new antibiotics requires patient-centered clinical outcomes. How to conduct a patient-centered benefit-risk assessment in the design, analysis, and interpretation of clinical trials, so that more bacterial clinical studies can achieve the expected efficacy? At the recently Infectious Disease Week (IDWeek 2023), "Infectious Disease Frontline" invited Dr. Thomas L. Holland from Duke University Medical Center to introduce the practical application and potential challenges of DOOR research on ordinal outcome, and shared its importance to future clinical trials and treatment plans.
IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

2023.11.30
Bacterial drug resistance is a significant challenge in the global public health field. Multidrug-resistant organisms (MDROs), represented by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and vancomycin-resistant Enterococcus (VRE), exhibit high resistance and rapid transmission. Previous studies have established a close relationship between intestinal CRE colonization and infection, but the relationship between intestinal colonization and infection of other MDROs remains to be clarified. In a recent oral presentation at the 2023 Infectious Diseases Week (IDWeek 2023), a researcher reported a study on the relationship between MDRO intestinal colonization and the risk of bloodstream infection (BSI). Dr. Yonghong Xiao, from the First Affiliated Hospital, Zhejiang University School of Medicine, provides an introduction and commentary on this research.
IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice

IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice

2023.11.30
In a special session titled "Clinical Trials That May Change Your Practice" at the 2023 Infectious Diseases Week (IDWeek 2023), Dr. George R. Thompson III of University of California Davis Medical Center presented a fascinating report on "Clinical Trials in Fungal Diseases That May Change Your Practice". He also granted an interview with "Infectious Disease Frontline"(IDF) after the conference.
Dr. Chun-rong Ju: Lung Transplant Recipients Receive Prolonged Contezolid Treatment for Nocardia InfectionDr. Chun-rong Ju: Lung Transplant Recipients

Dr. Chun-rong Ju: Lung Transplant Recipients Receive Prolonged Contezolid Treatment for Nocardia InfectionDr. Chun-rong Ju: Lung Transplant Recipients

2023.11.28
Nocardia is a conditional pathogen, and infections are common in immunocompromised populations such as organ transplant recipients. Professor Chunrong Ju and her team at the First Affiliated Hospital of Guangzhou Medical University's Respiratory and Critical Care Department and Transplant Department previously reported cases of Nocardia infection in lung transplant recipients (LTR) among the East Asian population [1,2]. During the 2023 IDWeek congress, Dr. Chun-rong Ju further presented the clinical outcomes of 18 LTR Nocardia infection patients who received treatment with the novel oxazolidinone-class drugs Linezolid or Contezolid. The results indicated that these novel oxazolidinone drugs were effective during prolonged anti-infection therapy in such patients and had fewer toxic side effects, including bone marrow suppression [3].